Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth

Therapeutic strategies aiming at mobilizing immune effector cells to kill tumor cells independent of tumor mutational load and MHC expression status are expected to benefit cancer patients. Recently, we engineered various peptide-Fc fusion proteins for directing Fcg receptor-bearing immune cells tow...

Descripción completa

Detalles Bibliográficos
Autores principales: Mobergslien, Anne, Peng, Qian, Vasovic, Vlada, Sioud, Mouldy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342789/
https://www.ncbi.nlm.nih.gov/pubmed/27713158
http://dx.doi.org/10.18632/oncotarget.12445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342789/
https://www.ncbi.nlm.nih.gov/pubmed/27713158
http://dx.doi.org/10.18632/oncotarget.12445

Ejemplares similares